# A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

> **NCT04271514** · PHASE1 · COMPLETED · sponsor: **RAPT Therapeutics, Inc.** · enrollment: 103 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** RPT193
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04271514
- **Lead sponsor:** RAPT Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-12
- **Primary completion:** 2021-04-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2021-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271514, "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT04271514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*